| |
Abstracts
of Key Research Articles
American Thoracic Society; European Respiratory Society Task Force on outcomes of COPD. Outcomes for COPD pharmacological trials: from lung function to biomarkers
Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, Brusasco V, Burge PS, Calverley PM, Celli BR, Jones PW, Mahler DA, Make B, Miravitlles M, Page CP, Palange P, Parr D, Pistolesi M, Rennard SI, Rutten-van Mölken MP, Stockley R, Sullivan SD, Wedzicha JA and Wouters EF
Eur Respir J 2008; 31: 416–469
TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease
Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC and Vestbo J
N Engl J Med 2007; 356: 775–789
Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial
Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, Balter M, O'Donnell D, McIvor A, Sharma S, Bishop G, Anthony J, Cowie R, Field S, Hirsch A, Hernandez P, Rivington R, Road J, Hoffstein V, Hodder R, Marciniuk D, McCormack D, Fox G, Cox G, Prins HB, Ford G, Bleskie D, Doucette S, Mayers I, Chapman K, Zamel N and FitzGerald M
Ann Intern Med 2007; 146: 545–555
Profiling serum biomarkers in patients with COPD: associations with clinical parameters
Pinto-Plata V, Toso J, Lee K, Park D, Bilello J, Mullerova H, De Souza MM, Vessey R and Celli B
Thorax. 2007; 62; 595–601
BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study
Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan SD, Lee TA, Weiss KB, Jensen RL, Marks GB, Gulsvik A and Nizankowska-Mogilnicka E
Lancet 2007; 370: 741–750
Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary
Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C and Zielinski J
Am J Respir Crit Care Med 2007; 176: 532–555
Mortality in COPD: role of comorbidities
Sin DD, Anthonisen NR, Soriano JB and Agusti AG
Eur Respir J 2006; 28: 1245–1257
From COPD to chronic systemic inflammatory syndrome?
Fabbri LM and Rabe KF
Lancet 2007; 370: 797–799
ATS/ERS Pulmonary Rehabilitation Writing Committee. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation
Nici L, Donner C, Wouters E, Zuwallack R, Ambrosino N, Bourbeau J, Carone M, Celli B, Engelen M, Fahy B, Garvey C, Goldstein R, Gosselink R, Lareau S, MacIntyre N, Maltais F, Morgan M, O'Donnell D, Prefault C, Reardon J, Rochester C, Schols A, Singh S and Troosters T
Am J Respir Crit Care Med 2006; 173: 1390–1413
Markers of disease severity in chronic obstructive pulmonary disease
Franciosi LG, Page CP, Celli BR, Cazzola M, Walker MJ, Danhof M, Rabe KF and Della Pasqua OE
Pulm Pharmacol Ther 2006; 19; 189–199
Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease
Mancini GB, Etminan M, Zhang B, Levesque LE, FitzGerald JM and Brophy JM
J Am Coll Cardiol 2006; 47: 2554–2560
|
